CoChat
Sign Up
Cited by 84

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The comprehensive landscape of miR-34a in cancer research

Li, Sijing, Wei, Xiaohui, He, Jinyong, Cao, Quanquan, Du, Danyu, Zhan, Xiaoman, Zeng, Yuqi, Yuan, Shengtao, Sun, Li·2021·Cancer and Metastasis Reviews
DOI 10.1007/s10555-021-09973-3
Open this paper in CoChat — free account

Abstract

MicroRNA-34 (miR-34) plays central roles in human diseases, especially cancers. Inactivation of miR-34 is detected in cancer cell lines and tumor tissues versus normal controls, implying its potential tumor-suppressive effect. Clinically, miR-34 has been identified as promising prognostic indicators for various cancers. In fact, members of the miR-34 family, especially miR-34a, have been convincingly proved to affect almost the whole cancer progression process. Here, a total of 512 (miR-34a, 10/21), 85 (miR-34b, 10/16), and 114 (miR-34c, 10/14) putative targets of miR-34a/b/c are predicted by at least ten miRNA databases, respectively. These targets are further analyzed in gene ontology (GO), KEGG pathway, and the Reactome pathway dataset. The results suggest their involvement in the regulation of signal transduction, macromolecule metabolism, and protein modification. Also, the targets are implicated in critical signaling pathways, such as MAPK, Notch, Wnt, PI3K/AKT, p53, and Ras, as well as apoptosis, cell cycle, and EMT-related pathways. Moreover, the upstream regulators of miR-34a, mainly including transcription factors (TFs), lncRNAs, and DNA methylation, will be summarized. Meanwhile, the potential TF upstream of miR-34a/b/c will be predicted by PROMO, JASPAR, Animal TFDB 3.0, and GeneCard databases. Notably, miR-34a is an attractive target for certain cancers. In fact, miR-34a-based systemic delivery combined with chemotherapy or radiotherapy can more effectively contr…

Overview

Integrity signals

Registry

Crossref · 10.1007/s10555-021-09973-3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 241

  1. Jiang, L., & Hermeking, H. (2017). miR-34a and miR-34b/c suppress intestinal tumorigenesis. Cancer Research, 77, 2746–2758. · DOI
  2. Kennerdell, J. R., Liu, N., & Bonini, N. M. (2018). MiR-34 inhibits polycomb repressive complex 2 to modulate chaperone expression and promote healthy brain aging. Nature Communications, 9, 4188–4200. · DOI · Paper page
  3. Liu, N., Landreh, M., Cao, K., Abe, M., Hendriks, G. J., Kennerdell, J. R., et al. (2012). The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila. Nature, 482, 519–523. · DOI · Paper page
  4. Xu, Q., Seeger, F. H., Castillo, J., Iekushi, K., Boon, R. A., Farcas, R., et al. (2012). Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease. Journal of the American College of Cardiology, 59, 2107–2117. · DOI
  5. Di Martino, M. T., Leone, E., Amodio, N., Foresta, U., Lionetti, M., Pitari, M. R., et al. (2012). Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence. Clinical Cancer Research, 18, 6260–6270. · DOI
  6. Zhang, L., Liao, Y., & Tang, L. (2019). MicroRNA-34 family: A potential tumor suppressor and therapeutic candidate in cancer. Journal of Experimental & Clinical Cancer Research, 38, 53–65. · DOI
  7. Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., et al. (2011). The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Medicine, 17, 211–215. · DOI
  8. Lou, W., Chen, Q., Ma, L., Liu, J., Yang, Z., Shen, J., et al. (2013). Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model. Journal of Molecular Medicine, 91, 715–725. · DOI
  9. Lin, X., Chen, W., Wei, F., Zhou, B. P., Hung, M. C., & Xie, X. (2017). Nanoparticle delivery of miR-34a eradicates long-term-cultured breast cancer stem cells via targeting C22ORF28 directly. Theranostics, 7, 4805–4824. · DOI
  10. Scognamiglio, I., Di Martino, M. T., Campani, V., Virgilio, A., Galeone, A., Gullà, A., et al. (2014). Transferrin-conjugated SNALPs encapsulating 2′-O-methylated miR-34a for the treatment of multiple myeloma. BioMed Research International, 2014, 217365–217372. · DOI
  11. Kasinski, A. L., Kelnar, K., Stahlhut, C., Orellana, E., Zhao, J., Shimer, E., et al. (2015). A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene, 34, 3547–3555. · DOI
  12. Tivnan, A., Orr, W. S., Gubala, V., Nooney, R., Williams, D. E., McDonagh, C., et al. (2012). Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One, 7, e38129–e38140. · DOI
  13. Pramanik, D., Campbell, N. R., Karikari, C., Chivukula, R., Kent, O. A., Mendell, J. T., et al. (2011). Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Molecular Cancer Therapeutics, 10, 1470–1480. · DOI
  14. Tiram, G., Segal, E., Krivitsky, A., Shreberk-Hassidim, R., Ferber, S., Ofek, P., et al. (2016). Identification of dormancy-associated microRNAs for the design of osteosarcoma-targeted dendritic polyglycerol nanopolyplexes. ACS Nano, 10, 2028–2045. · DOI
  15. Ofek, P., Calderón, M., Mehrabadi, F. S., Krivitsky, A., Ferber, S., Tiram, G., et al. (2016). Restoring the oncosuppressor activity of microRNA-34a in glioblastoma using a polyglycerol-based polyplex. Nanomedicine, 12, 2201–2214. · DOI
  16. Wang, S., Cao, M., Deng, X., Xiao, X., Yin, Z., Hu, Q., et al. (2015). Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. Advanced Healthcare Materials, 4, 281–290. · DOI
  17. Shatsberg, Z., Zhang, X., Ofek, P., Malhotra, S., Krivitsky, A., Scomparin, A., et al. (2016). Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy. Journal of Controlled Release, 239, 159–168. · DOI
  18. Jang, E., Kim, E., Son, H. Y., Lim, E. K., Lee, H., Choi, Y., et al. (2016). Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy. Biomaterials, 105, 12–24. · DOI
  19. Chen, W., Liu, Y., Liang, X., Huang, Y., & Li, Q. (2017). Chondroitin sulfate-functionalized polyamidoamine as a tumor-targeted carrier for miR-34a delivery. Acta Biomaterialia, 57, 238–250. · DOI
  20. Li, Y., Zhang, J., Zhang, L., Si, M., Yin, H., & Li, J. (2013). Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling. Carcinogenesis, 34, 1601–1610. · DOI
  21. Xiao, X., Chen, B., Liu, X., Liu, P., Zheng, G., Ye, F., et al. (2014). Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PLoS One, 9, e112720–e112726. · DOI
  22. Guo, J., Li, W., Shi, H., Xie, X., Li, L., Tang, H., et al. (2013). Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Molecular and Cellular Biochemistry, 382, 103–111. · DOI
  23. Norouzi, S., Majeed, M., Pirro, M., Generali, D., & Sahebkar, A. (2018). Curcumin as an adjunct therapy and microRNA modulator in breast cancer. Current Pharmaceutical Design, 24, 171–177. · DOI
  24. Kang, J., Kim, E., Kim, W., Seong, K. M., Youn, H., Kim, J. W., et al. (2013). Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. The Journal of Biological Chemistry, 288, 27343–27357. · DOI
  25. Jiang, Z. Q., Li, M. H., Qin, Y. M., Jiang, H. Y., Zhang, X., & Wu, M. H. (2018). Luteolin inhibits tumorigenesis and induces apoptosis of non-small cell lung cancer cells via regulation of microRNA-34a-5p. International Journal of Molecular Sciences, 19, 447–464. · DOI
  26. Zhou, B., Yi, H., Tan, J., Wu, Y., Liu, G., & Qiu, Z. (2015). Anti-proliferative effects of polyphenols from pomegranate rind (Punica granatum L.) on EJ bladder cancer cells via regulation of p53/miR-34a axis. Phytotherapy Research, 29, 415–422. · DOI
  27. Nadal, E., Chen, G., Gallegos, M., Lin, L., Ferrer-Torres, D., Truini, A., et al. (2013). Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Re, 19, 6842–6852. · DOI
  28. Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., et al. (2014). Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials, 35, 4333–4344. · DOI
  29. Yao, C., Liu, J., Wu, X., Tai, Z., Gao, Y., Zhu, Q., et al. (2016). Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. Journal of Controlled Release, 232, 203–214. · DOI
  30. Wang, Y., Chen, J., Liang, X., Han, H., Wang, H., & Yang, Y. (2017). An ATP-responsive codelivery system of doxorubicin and MiR-34a to synergistically inhibit cell proliferation and migration. Molecular Pharmaceutics, 14, 2323–2332. · DOI
  31. Shi, S., Han, L., Deng, L., Zhang, Y., Shen, H., Gong, T., et al. (2014). Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. Journal of Controlled Release, 194, 228–237. · DOI
  32. Gibori, H., Eliyahu, S., Krivitsky, A., Ben-Shushan, D., Epshtein, Y., Tiram, G., et al. (2018). (2018). Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer. Nature Communications, 9, 16–33. · DOI
  33. Li, L., Yuan, L., Luo, J., Gao, J., Guo, J., & Xie, X. (2013). MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clinical and Experimental Medicine, 13, 109–117. · DOI
  34. Yang, S., Li, Y., Gao, J., Zhang, T., Li, S., Luo, A., et al. (2013). MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene, 32, 4294–4303. · DOI
  35. Luo, D., Wilson, J. M., Harvel, N., Liu, J., Pei, L., Huang, S., et al. (2013). A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. Journal of Translational Medicine, 11, 57–70. · DOI
  36. Frères, P., Josse, C., Bovy, N., Boukerroucha, M., Struman, I., Bours, V., et al. (2015). Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression. Journal of Cellular Physiology, 230, 473–481. · DOI
  37. Imani, S., Zhang, X., Hosseinifard, H., Fu, S., & Fu, J. (2017). The diagnostic role of microRNA-34a in breast cancer: A systematic review and meta-analysis. Oncotarget, 8, 23177–23187. · DOI
  38. Agarwal, S., Hanna, J., Sherman, M. E., Figureueroa, J., & Rimm, D. L. (2015). Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. British Journal of Cancer, 112, 61–68. · DOI
  39. Liu, B., Su, F., Li, Y., Qi, X., Liu, X., Liang, W., et al. (2017). Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer. Biomedicine & Pharmacotherapy, 88, 911–917. · DOI
  40. Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K., & Schwarzenbach, H. (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research, 12, R90–R97. · DOI
  41. Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. (2013). Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clinical Chemistry, 59, 1489–1496. · DOI
  42. Chiu, L. Y., Kishnani, P. S., Chuang, T. P., Tang, C. Y., Liu, C. Y., Bali, D., et al. (2014). Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: A potential utility as biomarkers. Journal of Gastroenterology, 49, 1274–1284. · DOI
  43. Mizuguchi, Y., Mishima, T., Yokomuro, S., Arima, Y., Kawahigashi, Y., Shigehara, K., et al. (2011). Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One, 6, e15304–e15314. · DOI
  44. Xu, X., Chen, W., Miao, R., Zhou, Y., Wang, Z., Zhang, L., et al. (2015). miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway. Oncotarget, 6, 3988–4004. · DOI
  45. Dang, Y., Luo, D., Rong, M., & Chen, G. (2013). Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One, 8, e61054–e61064. · DOI
  46. Ren, F. H., Yang, H., He, R. Q., Lu, J. N., Lin, X. G., Liang, H. W., et al. (2018). Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma. BMC Cancer, 18, 12–21. · DOI
  47. Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., et al. (2009). miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Letters, 275, 44–53. · DOI
  48. Li, X., Lu, P., Li, B., Yang, R., Chu, Y., Zhang, Z., et al. (2016). Sensitization of hepatocellular carcinoma cells to irradiation by miR-34a through targeting lactate dehydrogenase-A. Molecular Medicine Reports, 13, 3661–3667. · DOI
  49. Xiang, Z. L., Zhao, X. M., Zhang, L., Yang, P., Fan, J., Tang, Z. Y., et al. (2016). MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. Oncotarget, 7, 87246–87256. · DOI
  50. Tian, Y. W., Shen, Q., Jiang, Q. F., Wang, Y. X., Li, K., & Xue, H. Z. (2017). Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma. Minerva Medica, 108, 108–113. · DOI
  51. Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B., et al. (2010). miR-221 overexpression contributes to liver tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 107, 264–269. · DOI
  52. Gougelet, A., Sartor, C., Bachelot, L., Godard, C., Marchiol, C., Renault, G., et al. (2016). Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut, 65, 1024–1034. · DOI
  53. Hu, Y., Pu, Q., Cui, B., & Lin, J. (2015). MicroRNA-34a inhibits tumor invasion and metastasis in gastric cancer by targeting Tgif2. International Journal of Clinical and Experimental Pathology, 8, 8921–8928.
  54. Cao, W., Yang, W., Fan, R., Li, H., Jiang, J., Geng, M., et al. (2014). miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biology, 35, 1287–1295. · DOI
  55. Peng, Y., Guo, J. J., Liu, Y. M., & Wu, X. L. (2014). MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Bioscience Reports, 34, e00112–e00122. · DOI
  56. Wang, A. M., Huang, T. T., Hsu, K. W., Huang, K. H., Fang, W. L., Yang, M. H., et al. (2014). Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. Oncotarget, 5, 5002–5016. · DOI
  57. Zhang, Z., Kong, Y., Yang, W., Ma, F., Zhang, Y., Ji, S., et al. (2016). Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncology Reports, 36, 2391–2397. · DOI
  58. Deng, X., Zheng, H., Li, D., Xue, Y., Wang, Q., Yan, S., et al. (2018). MicroRNA-34a regulates proliferation and apoptosis of gastric cancer cells by targeting silent information regulator 1. Experimental and Therapeutic Medicine, 15, 3705–3714.
  59. Zhou, Y., Ding, B. Z., Lin, Y. P., & Wang, H. B. (2018). MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. Gene, 644, 56–65. · DOI
  60. Zhou, Y., Huang, T., Siu, H. L., Wong, C. C., Dong, Y., Wu, F., et al. (2017). IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Molecular Cancer, 16, 77–90. · DOI
  61. Li, Y. L., Liu, X. M., Zhang, C. Y., Zhou, J. B., Shao, Y., Liang, C., et al. (2017). MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis. Oncogenesis, 6, e372–e382. · DOI
  62. Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G. V., Papotti, M., & Allgayer, H. (2011). Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene, 30, 2888–2899. · DOI
  63. Song, C., Lu, P., Sun, G., Yang, L., Wang, Z., & Wang, Z. (2017). miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis. Biochemical and Biophysical Research Communications, 482, 22–27. · DOI
  64. Lin, X., Lin, B. W., Chen, X. L., Zhang, B. L., Xiao, X. J., Shi, J. S., et al. (2017). PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in non-small cell lung cancer. Biochemical and Biophysical Research Communications, 493, 1464–1470. · DOI
  65. Gallardo, E., Navarro, A., Viñolas, N., Marrades, R. M., Diaz, T., Gel, B., et al. (2009). miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis, 30, 1903–1909. · DOI
  66. Zhao, K., Cheng, J., Chen, B., Liu, Q., Xu, D., & Zhang, Y. (2017). Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer. Journal of Thoracic Disease, 9, 3735–3746. · DOI
  67. Kashat, M., Azzouz, L., Sarkar, S. H., Kong, D., Li, Y., & Sarkar, F. H. (2012). Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. American Journal of Translational Research, 4, 432–442.
  68. Song, C. J., Chen, H., Chen, L. Z., Ru, G. M., Guo, J. J., & Ding, Q. N. (2018). The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies. Journal of Cellular Biochemistry, 119, 2763–2786. · DOI
  69. Kumar, B., Yadav, A., Lang, J., Teknos, T. N., & Kumar, P. (2012). Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One, 7, e37601–e37613. · DOI
  70. Nugent, M., Miller, N., & Kerin, M. J. (2012). Circulating miR-34a levels are reduced in colorectal cancer. Journal of Surgical Oncology, 106, 947–952. · DOI
  71. Zhang, D., Zhou, J., & Dong, M. (2014). Dysregulation of microRNA-34a expression in colorectal cancer inhibits the phosphorylation of FAK via VEGF. Digestive Diseases and Sciences, 59, 958–967. · DOI
  72. Yu, G., Yao, W., Xiao, W., Li, H., Xu, H., & Lang, B. (2014). MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. Journal of Experimental & Clinical Cancer Research, 33, 779–791. · DOI
  73. Yang, L., Song, X., Zhu, J., Li, M., Ji, Y., Wu, F., et al. (2017). Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. International Journal of Oncology, 51, 378–388. · DOI
  74. Li, Y., Guessous, F., Zhang, Y., Dipierro, C., Kefas, B., Johnson, E., et al. (2009). MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Research, 69, 7569–7576. · DOI · Paper page
  75. Dong, P., Xiong, Y., Watari, H., Hanley, S. J., Konno, Y., Ihira, K., et al. (2016). MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. Journal of Experimental & Clinical Cancer Research, 35, 132–140. · DOI
  76. Corney, D. C., Hwang, C. I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., et al. (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clinical Cancer Research, 16, 1119–1128. · DOI
  77. Liu, J., Ma, L., Li, C., Zhang, Z., Yang, G., & Zhang, W. (2013). Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells. Molecular Oncology, 7, 1043–1055. · DOI
  78. Marino, M. T., Grilli, A., Baricordi, C., Manara, M. C., Ventura, S., Pinca, R. S., et al. (2014). Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression. Annals of Oncology, 25, 2080–2086. · DOI
  79. Chen, L., Yang, C., Feng, J., Liu, X., Tian, Y., Zhao, L., et al. (2017). Clinical significance of miR-34a expression in thyroid diseases - An (18)F-FDG PET-CT study. Cancer Management and Research, 9, 903–913. · DOI
  80. Toraih, E. A., & Ibrahiem, A. T. (2017). MicroRNA-34a: A key regulator in the hallmarks of renal cell carcinoma. Oxidative Medicine and Cellular Longevity, 2017, 3269379–3269390. · DOI
  81. Vychytilova-Faltejskova, P., Kiss, I., Klusova, S., Hlavsa, J., Prochazka, V., Kala, Z., et al. (2015). MiR-21, miR-34a,miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagnostic Pathology, 10, 38–42. · DOI
  82. Wang, X., Li, J., Dong, K., Lin, F., Long, M., Ouyang, Y., et al. (2015). Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cellular Signalling, 27, 443–452. · DOI
  83. Hashemi, M., Bahari, G., Naderi, M., Sadeghi-Bojd, S., & Taheri, M. (2016). Pri-miR-34b/c rs4938723 polymorphism is associated with the risk of childhood acute lymphoblastic leukemia. Cancer Genetics, 209, 493–496. · DOI
  84. Tong, N., Chu, H., Wang, M., Xue, Y., Du, M., Lu, L., et al. (2016). Pri-miR-34b/c rs4938723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children. Leukemia & Lymphoma, 57, 1436–1441. · DOI
  85. He, J., Zou, Y., Liu, X., Zhu, J., Zhang, J., Zhang, R., et al. (2018). Association of common genetic variants in pre-microRNAs and neuroblastoma susceptibility: A two-center study in Chinese children. Molecular Therapy--Nucleic Acids, 11, 1–8. · DOI
  86. Li, L., Zhu, J., Lu, T., Liu, W., Tang, J., Zhang, J., et al. (2019). Association of miR-34b/c rs4938723 and TP53 Arg72Pro polymorphisms with neuroblastoma susceptibility: Evidence from seven centers. Translational Oncology, 12, 1282–1288. · DOI
  87. Li, Y., Zhuo, Z. J., Zhou, H., Liu, J., Xiao, Z., Xiao, Y., et al. (2019). miR-34b/c rs4938723 T>C decreases neuroblastoma risk: A replication study in the Hunan children. Disease Markers, 2019, 6514608–6514615. · DOI
  88. Liu, P., Zhuo, Z. J., Zhu, J., Yang, Z., Xin, Y., Li, S., et al. (2020). Association of TP53 rs1042522 C>G and miR-34b/c rs4938723 T>C polymorphisms with hepatoblastoma susceptibility: A seven-center case-control study. The Journal of Gene Medicine, 22, e3182–e3189. · DOI
  89. Jiao, C., Zhu, A., Jiao, X., Ge, J., & Xu, X. (2016). Combined low miR-34s are associated with unfavorable prognosis in children with hepatoblastoma: A Chinese population-based study. Journal of Pediatric Surgery, 51, 1355–1361. · DOI
  90. Karami, A., Sadeghian, M., Azizi, M., & Asaadi, T. G. (2019). Aberrant promoter hypermethylation of Mir34a and Mir200b Genes in pediatric acute lymphoblastic leukemia. Iranian Journal of Pediatrics, 29, e89226–e89232. · DOI
  91. Cao, L., Wang, N., Pan, J., Hu, S., Zhao, W., He, H., et al. (2016). Clinical significance of microRNA-34b expression in pediatric acute leukemia. Molecular Medicine Reports, 13, 2777–2784. · DOI
  92. Thor, T., Künkele, A., Pajtler, K. W., Wefers, A. K., Stephan, H., Mestdagh, P., et al. (2015). MiR-34a deficiency accelerates medulloblastoma formation in vivo. International Journal of Cancer, 136, 2293–2303. · DOI
  93. Weeraratne, S. D., Amani, V., Neiss, A., Teider, N., Scott, D. K., Pomeroy, S. L., et al. (2011). miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro-oncology, 13, 165–175. · DOI
  94. Bettinsoli, P., Ferrari-Toninelli, G., Bonini, S. A., Prandelli, C., & Memo, M. (2017). Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma. BMC Cancer, 17, 352–364. · DOI
  95. Darrigo Júnior, L. G., Lira, R. C. P., Fedatto, P. F., Marco Antonio, D. S., Valera, E. T., Aguiar, S., et al. (2019). MicroRNA profile of pediatric pilocytic astrocytomas identifies two tumor-specific signatures when compared to non-neoplastic white matter. Journal of Neuro-Oncology, 141, 373–382. · DOI
  96. Birks, D. K., Barton, V. N., Donson, A. M., Handler, M. H., Vibhakar, R., & Foreman, N. K. (2011). Survey of MicroRNA expression in pediatric brain tumors. Pediatric Blood & Cancer, 56, 211–216. · DOI
  97. Costa, F. F., Bischof, J. M., Vanin, E. F., Lulla, R. R., Wang, M., Sredni, S. T., et al. (2011). Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One, 6, e25114–e25124. · DOI
  98. Bayraktar, R., Ivan, C., Bayraktar, E., Kanlikilicer, P., Kabil, N. N., Kahraman, N., et al. (2018). Dual suppressive effect of miR-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion. Clinical Cancer Research, 24, 4225–4241. · DOI
  99. Liu, K., Huang, J., Xie, M., Yu, Y., Zhu, S., Kang, R., et al. (2014). MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy, 10, 442–452. · DOI
  100. Xiao, X., Huang, X., Ye, F., Chen, B., Song, C., Wen, J., et al. (2016). The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Scientific Reports, 6, 21735–21742. · DOI
  101. Zhao, G., Guo, J., Li, D., Jia, C., Yin, W., Sun, R., et al. (2013). MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. DNA and Cell Biology, 32, 699–707. · DOI
  102. Wang, Y., Zhang, X., Chao, Z., Kung, H. F., Lin, M. C., Dress, A., et al. (2017). MiR-34a modulates ErbB2 in breast cancer. Cell Biology International, 41, 93–101. · DOI
  103. Xu, M., Li, D., Yang, C., & Ji, J. S. (2018). MicroRNA-34a inhibition of the TLR signaling pathway via CXCL10 suppresses breast cancer cell invasion and migration. Cellular Physiology and Biochemistry, 46, 1286–1304. · DOI
  104. Park, E. Y., Chang, E., Lee, E. J., Lee, H. W., Kang, H. G., Chun, K. H., et al. (2014). Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Research, 74, 7573–7582. · DOI
  105. Si, W., Li, Y., Shao, H., Hu, R., Wang, W., Zhang, K., et al. (2016). MiR-34a inhibits breast cancer proliferation and progression by targeting Wnt1 in Wnt/β-catenin signaling pathway. The American Journal of the Medical Sciences, 352, 191–199. · DOI
  106. Garofalo, M., Jeon, Y. J., Nuovo, G. J., Middleton, J., Secchiero, P., Joshi, P., et al. (2013). MiR-34a/c-dependent PDGFR-α/β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. PLoS One, 8, e67581–e67592. · DOI
  107. Han, Z., Zhang, Y., Yang, Q., Liu, B., Wu, J., Zhang, Y., et al. (2015). miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget, 6, 13149–13163. · DOI
  108. Zhang, H. F., Wang, Y. C., & Han, Y. D. (2018). MicroRNA-34a inhibits liver cancer cell growth by reprogramming glucose metabolism. Molecular Medicine Reports, 17, 4483–4489.
  109. Cheng, L., Gao, S., Song, X., Dong, W., Zhou, H., Zhao, L., et al. (2016). Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs. Oncotarget, 7, 61199–61214. · DOI
  110. Yamamura, S., Saini, S., Majid, S., Hirata, H., Ueno, K., Deng, G., et al. (2012). MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One, 7, e29722–e29733. · DOI
  111. Chakravarthi, B., Chandrashekar, D. S., Agarwal, S., Balasubramanya, S. A. H., Pathi, S. S., Goswami, M. T., et al. (2018). miR-34a regulates expression of the Stathmin-1 oncoprotein and prostate cancer progression. Molecular Cancer Research, 16, 1125–1137. · DOI
  112. Wu, X., Zhong, D., Gao, Q., Zhai, W., Ding, Z., & Wu, J. (2013). MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression. International Journal of Medical Sciences, 10, 676–682. · DOI
  113. Vetter, N. S., Kolb, E. A., Mills, C. C., & Sampson, V. B. (2017). The microtubule network and cell death are regulated by an miR-34a/Stathmin 1/βIII-tubulin axis. Molecular Cancer Research, 15, 953–964. · DOI
  114. de Antonellis, P., Medaglia, C., Cusanelli, E., Andolfo, I., Liguori, L., De Vita, G., et al. (2011). MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One, 6, e24584–e24600. · DOI
  115. El Bezawy, R., De Cesare, M., Pennati, M., Deraco, M., Gandellini, P., Zuco, V., et al. (2017). Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. Journal of Hematology & Oncology, 10, 19–32. · DOI
  116. Sun, H., Tian, J., Xian, W., Xie, T., & Yang, X. (2015). miR-34a inhibits proliferation and invasion of bladder cancer cells by targeting orphan nuclear receptor HNF4G. Disease Markers, 2015, 879254–879262. · DOI
  117. Liu, R., Xie, H., Luo, C., Chen, Z., Zhou, X., Xia, K., et al. (2015). Identification of FLOT2 as a novel target for microRNA-34a in melanoma. Journal of Cancer Research and Clinical Oncology, 141, 993–1006. · DOI
  118. Li, S., Luo, C., Zhou, J., & Zhang, Y. (2017). MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma. Experimental and Therapeutic Medicine, 14, 5611–5618.
  119. Lv, T., Song, K., Zhang, L., Li, W., Chen, Y., Diao, Y., et al. (2018). miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. Biochemistry and Cell Biology, 96, 663–671. · DOI
  120. Zhang, R., Su, J., Xue, S. L., Yang, H., Ju, L. L., Ji, Y., et al. (2016). HPV E6/p53 mediated down-regulation of miR-34a inhibits Warburg effect through targeting LDHA in cervical cancer. American Journal of Cancer Research, 6, 312–320.
  121. Li, C., Wang, Y., Lu, S., Zhang, Z., Meng, H., Liang, L., et al. (2015). MiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α. Molecular Medicine Reports, 12, 7072–7078. · DOI
  122. Wang, Z., Wang, W., Huang, K., Wang, Y., Li, J., & Yang, X. (2017). MicroRNA-34a inhibits cells proliferation and invasion by downregulating Notch1 in endometrial cancer. Oncotarget, 8, 111258–111270. · DOI
  123. Pang, R. T., Leung, C. O., Lee, C. L., Lam, K. K., Ye, T. M., Chiu, P. C., et al. (2013). MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Delta-like1. BMC Cancer, 13, 25–34. · DOI
  124. Yang, Y., Ding, L., Guo, Z. K., Zheng, X. L., Wang, L. S., Sun, H. Y., et al. (2017). The epigenetically-regulated miR-34a targeting c-SRC suppresses RAF/MEK/ERK signaling pathway in K-562 cells. Leukemia Research, 55, 91–96. · DOI
  125. Craig, V. J., Cogliatti, S. B., Imig, J., Renner, C., Neuenschwander, S., Rehrauer, H., et al. (2011). Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood, 117, 6227–6236. · DOI
  126. Lu, G., Sun, Y., An, S., Xin, S., Ren, X., Zhang, D., et al. (2015). MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. Experimental and Molecular Pathology, 99, 173–179. · DOI
  127. Öner, M. G., Rokavec, M., Kaller, M., Bouznad, N., Horst, D., Kirchner, T., et al. (2018). Combined inactivation of TP53 and MIR34A promotes colorectal cancer development and progression in mice via increasing levels of IL6R and PAI1. Gastroenterology, 155, 1868–1882. · DOI
  128. Li, H., Rokavec, M., Jiang, L., Horst, D., & Hermeking, H. (2017). Antagonistic effects of p53 and HIF1A on microRNA-34a regulation of PPP1R11 and STAT3 and hypoxia-induced epithelial to mesenchymal transition in colorectal cancer cells. Gastroenterology, 153, 505–520. · DOI
  129. Hahn, S., Jackstadt, R., Siemens, H., Hünten, S., & Hermeking, H. (2013). SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. The EMBO Journal, 32, 3079–3095. · DOI
  130. Siemens, H., Jackstadt, R., Kaller, M., & Hermeking, H. (2013). Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget, 4, 1399–1415. · DOI
  131. Li, Y., Zeng, C., Hu, J., Pan, Y., Shan, Y., Liu, B., et al. (2018). Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression. Journal of Hematology & Oncology, 11, 89–105. · DOI
  132. Fujita, Y., Kojima, K., Hamada, N., Ohhashi, R., Akao, Y., Nozawa, Y., et al. (2008). Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochemical and Biophysical Research Communications, 377, 114–119. · DOI
  133. Wen, D., Peng, Y., Lin, F., Singh, R. K., & Mahato, R. I. (2017). Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer. Cancer Research, 77, 3244–3254. · DOI
  134. Li, X. J., Ji, M. H., Zhong, S. L., Zha, Q. B., Xu, J. J., Zhao, J. H., et al. (2012). MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Archives of Medical Research, 43, 514–521. · DOI
  135. Adams, B. D., Wali, V. B., Cheng, C. J., Inukai, S., Booth, C. J., Agarwal, S., et al. (2016). miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer. Cancer Research, 76, 927–939. · DOI
  136. Kang, L., Mao, J., Tao, Y., Song, B., Ma, W., Lu, Y., et al. (2015). MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Science, 106, 700–708. · DOI
  137. Hao, Q., Lu, X., Liu, N., Xue, X., Li, M., Zhang, C., et al. (2013). Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development. BMB Reports, 46, 316–321. · DOI
  138. Liu, Y. W., Sun, M., Xia, R., Zhang, E. B., Liu, X. H., Zhang, Z. H., et al. (2015). LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death & Disease, 6, e1802–e1810. · DOI
  139. Ahn, Y. H., Gibbons, D. L., Chakravarti, D., Creighton, C. J., Rizvi, Z. H., Adams, H. P., et al. (2012). ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. The Journal of Clinical Investigation, 122, 3170–3183. · DOI
  140. Chen, W. Y., Liu, S. Y., Chang, Y. S., Yin, J. J., Yeh, H. L., Mouhieddine, T. H., et al. (2015). MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. Oncotarget, 6, 441–457. · DOI
  141. Liang, J., Li, Y., Daniels, G., Sfanos, K., De Marzo, A., Wei, J., et al. (2015). LEF1 targeting EMT in prostate cancer invasion is regulated by miR-34a. Molecular Cancer Research, 13, 681–688. · DOI
  142. Nie, J., Ge, X., Geng, Y., Cao, H., Zhu, W., Jiao, Y., et al. (2015). miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. Oncology Reports, 34, 311–317. · DOI
  143. Bernardi, C., Soffientini, U., Piacente, F., & Tonetti, M. G. (2013). Effects of microRNAs on fucosyltransferase 8 (FUT8) expression in hepatocarcinoma cells. PLoS One, 8, e76540–e76546. · DOI
  144. Yu, G., Li, H., Wang, J., Gumireddy, K., Li, A., Yao, W., et al. (2014). miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells. The Journal of Urology, 192, 1229–1237. · DOI
  145. Yan, K., Gao, J., Yang, T., Ma, Q., Qiu, X., Fan, Q., et al. (2012). MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One, 7, e33778–e33788. · DOI
  146. Schirmer, U., Doberstein, K., Rupp, A. K., Bretz, N. P., Wuttig, D., Kiefel, H., et al. (2014). Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget, 5, 462–472. · DOI
  147. Qiao, P., Li, G., Bi, W., Yang, L., Yao, L., & Wu, D. (2015). microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. BMC Cancer, 15, 469–481. · DOI
  148. Huang, G., Du, M. Y., Zhu, H., Zhang, N., Lu, Z. W., Qian, L. X., et al. (2018). MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells. Biomedicine & Pharmacotherapy, 106, 217–224. · DOI
  149. Li, T., Li, L., Li, D., Wang, S., & Sun, J. (2015). MiR-34a inhibits oral cancer progression partially by repression of interleukin-6-receptor. International Journal of Clinical and Experimental Pathology, 8, 1364–1373.
  150. Zhang, J., Wang, Y., Chen, X., Zhou, Y., Jiang, F., Chen, J., et al. (2015). MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC). Oncotarget, 6, 7454–7469. · DOI
  151. Li, X., Zhao, H., Zhou, X., & Song, L. (2015). Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. Molecular Medicine Reports, 11, 577–582. · DOI
  152. Wu, M. Y., Fu, J., Xiao, X., Wu, J., & Wu, R. C. (2014). MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer Letters, 354, 311–319. · DOI
  153. Kim do, Y., Park, E. Y., Chang, E., Kang, H. G., Koo, Y., Lee, E. J., et al. (2016). A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer. Oncotarget, 7, 14791–14802. · DOI
  154. Sun, C., Wang, F. J., Zhang, H. G., Xu, X. Z., Jia, R. C., Yao, L., et al. (2017). miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway. World Journal of Gastroenterology, 23, 1816–1827. · DOI
  155. Liu, X., Luo, X., Wu, Y., Xia, D., Chen, W., Fang, Z., et al. (2018). MicroRNA-34a attenuates paclitaxel resistance in prostate cancer cells via direct suppression of JAG1/Notch1 axis. Cellular Physiology and Biochemistry, 50, 261–276. · DOI
  156. Liao, H., Xiao, Y., Hu, Y., Xiao, Y., Yin, Z., Liu, L., et al. (2016). Methylation-induced silencing of miR-34a enhances chemoresistance by directly upregulating ATG4B-induced autophagy through AMPK/mTOR pathway in prostate cancer. Oncology Reports, 35, 64–72. · DOI
  157. Yang, F., Li, Q. J., Gong, Z. B., Zhou, L., You, N., Wang, S., et al. (2014). MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technology in Cancer Research & Treatment, 13, 77–86. · DOI
  158. Wang, Y., & Wang, L. (2017). miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1. Biotechnology Letters, 39, 1485–1492. · DOI
  159. Li, Q. C., Xu, H., Wang, X., Wang, T., & Wu, J. (2017). miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal. Cancer Biomarkers, 21, 135–144. · DOI
  160. Zhang, Q., Zhuang, J., Deng, Y., Yang, L., Cao, W., Chen, W., et al. (2017). miR34a/GOLPH3 axis abrogates urothelial bladder cancer chemoresistance via reduced cancer stemness. Theranostics, 7, 4777–4790. · DOI
  161. Liu, X., Liu, X., Wu, Y., Fang, Z., Wu, Q., Wu, C., et al. (2018). MicroRNA-34a attenuates metastasis and chemoresistance of bladder cancer cells by targeting the TCF1/LEF1 axis. Cellular Physiology and Biochemistry, 48, 87–98. · DOI
  162. Pu, Y., Zhao, F., Li, Y., Cui, M., Wang, H., Meng, X., et al. (2017). The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. BMC Cancer, 17, 45–53. · DOI
  163. Pu, Y., Zhao, F., Wang, H., Cai, W., Gao, J., Li, Y., et al. (2016). MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. Oncotarget, 7, 28420–28434. · DOI
  164. Cho, C. Y., Huang, J. S., Shiah, S. G., Chung, S. Y., Lay, J. D., Yang, Y. Y., et al. (2016). Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells. RNA, 22, 303–315. · DOI
  165. Duan, J., Zhou, K., Tang, X., Duan, J., & Zhao, L. (2016). MicroRNA-34a inhibits cell proliferation and induces cell apoptosis of glioma cells via targeting of Bcl-2. Molecular Medicine Reports, 14, 432–438. · DOI
  166. Dong, X., Jin, Z., Chen, Y., Xu, H., Ma, C., Hong, X., et al. (2018). Knockdown of long non-coding RNA ANRIL inhibits proliferation, migration, and invasion but promotes apoptosis of human glioma cells by upregulation of miR-34a. Journal of Cellular Biochemistry, 119, 2708–2718. · DOI
  167. Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008). miR-34a repression of SIRT1 regulates apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 105, 13421–13426. · DOI
  168. Liu, L., Ren, W., & Chen, K. (2017). MiR-34a promotes apoptosis and inhibits autophagy by targeting HMGB1 in acute myeloid leukemia cells. Cellular Physiology and Biochemistry, 41, 1981–1992. · DOI
  169. Sun, T. Y., Xie, H. J., Li, Z., Kong, L. F., Gou, X. N., Li, D. J., et al. (2017). miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma. American Journal of Translational Research, 9, 103–114.
  170. Welch, C., Chen, Y., & Stallings, R. L. (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, 26, 5017–5022. · DOI
  171. Shen, Z., Zhan, G., Ye, D., Ren, Y., Cheng, L., Wu, Z., et al. (2012). MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Medical Oncology, 29, 2473–2480. · DOI
  172. Xia, J., Duan, Q., Ahmad, A., Bao, B., Banerjee, S., Shi, Y., et al. (2012). Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Current Drug Targets, 13, 1750–1756. · DOI
  173. Wang, B., Li, D., Kovalchuk, I., Apel, I. J., Chinnaiyan, A. M., Wóycicki, R. K., et al. (2018). miR-34a directly targets tRNA(i)(Met) precursors and affects cellular proliferation, cell cycle, and apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 115, 7392–7397. · DOI
  174. Zauli, G., Voltan, R., di Iasio, M. G., Bosco, R., Melloni, E., Sana, M. E., et al. (2011). miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clinical Cancer Research, 17, 2712–2724. · DOI
  175. Ren, J., Ding, L., Xu, Q., Shi, G., Li, X., & Li, X. (2017). LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway. Scientific Reports, 7, 749–760. · DOI
  176. Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., et al. (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Letters, 582, 1564–1568. · DOI
  177. Cortez, M. A., Valdecanas, D., Niknam, S., Peltier, H. J., Diao, L., Giri, U., et al. (2015). In vivo delivery of miR-34a Sensitizes lung tumors to radiation through RAD51 regulation. Molecular Therapy--Nucleic Acids, 4, e270–e278. · DOI
  178. Pieraccioli, M., Nicolai, S., Pitolli, C., Agostini, M., Antonov, A., & Malewicz, M. (2018). ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 115, 7356–7361. · DOI
  179. Lefort, K., Brooks, Y., Ostano, P., Cario-André, M., Calpini, V., Guinea-Viniegra, J., et al. (2013). A miR-34a-SIRT6 axis in the squamous cell differentiation network. The EMBO Journal, 32, 2248–2263. · DOI
  180. Deng, J., Yang, M., Jiang, R., An, N., Wang, X., & Liu, B. (2017). Long non-coding RNA HOTAIR regulates the proliferation, self-renewal capacity, tumor formation and migration of the cancer stem-like cell (CSC) subpopulation enriched from breast cancer cells. PLoS One, 12, e0170860–e0170874. · DOI
  181. Ma, W., Xiao, G. G., Mao, J., Lu, Y., Song, B., Wang, L., et al. (2015). Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. Oncotarget, 6, 10432–10444. · DOI
  182. Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., et al. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular Cell, 26, 731–743. · DOI
  183. Kim, N. H., Kim, H. S., Li, X. Y., Lee, I., Choi, H. S., Kang, S. E., et al. (2011). A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. The Journal of Cell Biology, 195, 417–433. · DOI
  184. Hwang, C. I., Matoso, A., Corney, D. C., Flesken-Nikitin, A., Körner, S., Wang, W., et al. (2011). Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proceedings of the National Academy of Sciences of the United States of America, 108, 14240–14245. · DOI
  185. Luan, S., Sun, L., & Huang, F. (2010). MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Archives of Medical Research, 41, 67–74. · DOI
  186. Xiao, Z., Li, C. H., Chan, S. L., Xu, F., Feng, L., Wang, Y., et al. (2014). A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Research, 74, 6236–6247. · DOI
  187. Dijkstra, M. K., van Lom, K., Tielemans, D., Elstrodt, F., Langerak, A. W., van’t Veer, M. B., et al. (2009). 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia, 23, 625–627. · DOI
  188. Choi, Y. J., Lin, C. P., Ho, J. J., He, X., Okada, N., Bu, P., et al. (2011). miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nature Cell Biology, 13, 1353–1360. · DOI
  189. Christoffersen, N. R., Shalgi, R., Frankel, L. B., Leucci, E., Lees, M., Klausen, M., et al. (2010). p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death and Differentiation, 17, 236–245. · DOI · Paper page
  190. Galtsidis, S., Logotheti, S., Pavlopoulou, A., Zampetidis, C. P., Papachristopoulou, G., Scorilas, A., et al. (2017). Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness. Cancer Letters, 388, 96–106. · DOI
  191. Su, X., Chakravarti, D., Cho, M. S., Liu, L., Gi, Y. J., Lin, Y. L., et al. (2010). TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature, 467, 986–990. · DOI
  192. Li, J., Wang, K., Chen, X., Meng, H., Song, M., Wang, Y., et al. (2012). Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Molecular Biology, 13, 4–13. · DOI
  193. Wang, X., Wang, C., Zhang, X., Hua, R., Gan, L., Huang, M., et al. (2016). Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs. Journal of Hematology & Oncology, 9, 90–107. · DOI
  194. Pulikkan, J. A., Peramangalam, P. S., Dengler, V., Ho, P. A., Preudhomme, C., Meshinchi, S., et al. (2010). C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood, 116, 5638–5649. · DOI
  195. Peurala, H., Greco, D., Heikkinen, T., Kaur, S., Bartkova, J., Jamshidi, M., et al. (2011). MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS One, 6, e26122–e26131. · DOI
  196. Iqbal, N., Mei, J., Liu, J., & Skapek, S. X. (2014). miR-34a is essential for p19(Arf)-driven cell cycle arrest. Cell Cycle, 13, 792–800. · DOI
  197. Chen, C., Bai, L., & Cao, F. (2019). Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis. Oncogene, 38, 4527–4539. · DOI
  198. Xu, T. P., Ma, P., Wang, W. Y., Shuai, Y., Wang, Y. F., Yu, T., et al. (2019). KLF5 and MYC modulated LINC00346 contributes to gastric cancer progression through acting as a competing endogenous RNA and indicates poor outcome. Cell Death and Differentiation, 26, 2179–2193. · DOI
  199. Siemens, H., Jackstadt, R., Hünten, S., Kaller, M., Menssen, A., Götz, U., et al. (2011). miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle, 10, 4256–4271. · DOI
  200. Anastasiadou, E., Stroopinsky, D., Alimperti, S., Jiao, A. L., Pyzer, A. R., Cippitelli, C., et al. (2019). Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia, 33, 132–147. · DOI

200 of 241 shown

Cited by

Sorted by citations

Metadata

Authors
Li, S., Wei, X., He, J., Cao, Q., Du, D., Zhan, X., Zeng, Y., Yuan, S., & Sun, L.
Venue
Cancer and Metastasis Reviews
Publisher
Springer Science and Business Media LLC
Published
2021-05-06
Volume
40
Issue
3
Pages
925-948
ISSN
  • 0167-7659
  • 1573-7233
DOI
10.1007/s10555-021-09973-3
Cited by
84
References
1
Language
en
Licence
Funders
  • National Natural Science Foundation of China (No. 81573456, No.81872892, No.81773766, No.82003811)
  • Natural Science Foundation of Anhui Province (No. 2008085QH403)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review